Cosmo close to breakeven this year
This article was originally published in Scrip
Executive Summary
Italian gastrointestinal disease specialist Cosmo Pharmaceuticals expects its financial results to be close to breakeven this year, because of increasing revenues from the sale of Lialda (once-daily mesalamine, marketed by Shire) in the US.